It has been shown that CCNA2 can be a key target for the treatment of lung adenocarcinoma, and abnormal expression of CCNA2 plays a critical role in the development of lung adenocarcinoma.[37] In addition, it has been shown that CCNA2 has a protective effect on innate immune responses and helps to reduce pathogen-induced inflammation and apoptosis, while CCNA2 is also critical for the regulation of immune-related gene expression.[38] CCNB1, a member of the G2/mitotic-specific cyclin B1 family, controls the transition from G2 to M phase, is expressed in G2 phase and degraded in M phase. The gene discussed is CCNA2; the disease is lung adenocarcinoma.